HomeCompareORKLY vs JNJ

ORKLY vs JNJ: Dividend Comparison 2026

ORKLY yields 3.08% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORKLY wins by $474.29M in total portfolio value
10 years
ORKLY
ORKLY
● Live price
3.08%
Share price
$12.65
Annual div
$0.39
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$474.32M
Annual income
$446,491,578.59
Full ORKLY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ORKLY vs JNJ

📍 ORKLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORKLYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORKLY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORKLY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORKLY
Annual income on $10K today (after 15% tax)
$261.99/yr
After 10yr DRIP, annual income (after tax)
$379,517,841.80/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ORKLY beats the other by $379,513,855.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORKLY + JNJ for your $10,000?

ORKLY: 50%JNJ: 50%
100% JNJ50/50100% ORKLY
Portfolio after 10yr
$237.17M
Annual income
$223,248,134.00/yr
Blended yield
94.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ORKLY
Analyst Ratings
1
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
4.0
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORKLY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORKLYJNJ
Forward yield3.08%2.13%
Annual dividend / share$0.39$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$474.32M$30.3K
Annual income after 10y$446,491,578.59$4,689.40
Total dividends collected$472.27M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ORKLY vs JNJ ($10,000, DRIP)

YearORKLY PortfolioORKLY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,316$616.45$10,592$272.30+$724.00ORKLY
2$13,413$1,303.94$11,289$357.73+$2.1KORKLY
3$17,240$2,888.72$12,123$472.89+$5.1KORKLY
4$25,387$6,940.34$13,141$629.86+$12.2KORKLY
5$46,267$19,103.03$14,408$846.81+$31.9KORKLY
6$114,580$65,074.01$16,021$1,151.60+$98.6KORKLY
7$423,824$301,222.77$18,122$1,588.22+$405.7KORKLY
8$2,536,110$2,082,618.34$20,930$2,228.20+$2.52MORKLY
9$26,007,357$23,293,719.59$24,792$3,191.91+$25.98MORKLY
10$474,319,450$446,491,578.59$30,274$4,689.40+$474.29MORKLY

ORKLY vs JNJ: Complete Analysis 2026

ORKLYStock

Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery retail trade, as well as the out-of-home, convenience store, and petrol station sectors. It also provides confectionery, biscuit, and snack products; and develops crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic garments; and professional cleaning products. Further, it operates Gymgrossisten and Bodystore e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, Abba, Kalles, Beauvais, Den Gamle Fabrik, Spilva, Vitana, MTR, and Eastern brands; confectionery and snacks under the KiMs, Nidar, Stratos, Göteborgs Kex, Sætre, OLW, Panda, Laima, Selga, Taffel, Adazu, and Kalev brands; health and sports nutrition under Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under Odense, Mors Hjemmebakte, KronJäst, Bakkedal and NATURLI' brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company is headquartered in Oslo, Norway.

Full ORKLY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ORKLY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORKLY vs SCHDORKLY vs JEPIORKLY vs OORKLY vs KOORKLY vs MAINORKLY vs ABBVORKLY vs MRKORKLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.